Drugs /

autologous anti-cll-1-car t-lymphocytes kite-222

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of autologous T-lymphocytes expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) C-type-lectin-like molecule-1 (CLL-1; CLL1; C-type lectin domain family 12 member A; CLEC12A), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CLL-1-CAR T-lymphocytes KITE-222 specifically target and bind to CLL-1-expressing tumor cells. This induces selective toxicity in tumor cells that express the CLL-1 antigen. CLL-1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) and plays an important role in disease progression and relapse for myeloid malignancies.

Clinical Trials

View Clinical Trials for autologous anti-cll-1-car t-lymphocytes kite-222

Autologous anti-cll-1-car t-lymphocytes kite-222 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating autologous anti-cll-1-car t-lymphocytes kite-222, 1 is phase 1 (1 open).

PML-RARA Fusion, t(15;17)(q22;q12), and t(15;17)(q24;q21) are the most frequent biomarker inclusion criteria for autologous anti-cll-1-car t-lymphocytes kite-222 clinical trials.

Acute myeloid leukemia and secondary acute myeloid leukemia are the most common diseases being investigated in autologous anti-cll-1-car t-lymphocytes kite-222 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Autologous Anti-Cll-1-Car T-Lymphocytes Kite-222
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating autologous anti-cll-1-car t-lymphocytes kite-222 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
autologous anti-cll-1-car t-cells kite-222, autologous anti-cll1-car-t cells kite-222, kite 222, kite-222, kite222
Drug Target(s) [2]:
CLEC12A
NCIT ID [1]:
C178486

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.